Allergic asthma is one of the most common chronic diseases, resulting in a substantial burden of disease. Although rates of deaths caused by asthma worldwide have decreased greatly over the past 25 years, no available therapeutic regimens can yet cure this complex disease. Current clinical therapies are based on inhalation of corticosteroids and long-acting b 2 -agonists and are effective in controlling asthma in most but not all patients. 1 Asthma is a chronic inflammatory disease of the airways characterized by infiltration of eosinophils, basophils, mast cells, and CD4 T H cells into the airway submucosa, causing lung inflammation. T H 2 cells and type 2 innate lymphoid cells, which produce IL-4, IL-5, and IL-13, are now recognized as important mediators of allergic eosinophilic asthma. 2, 3 Other important players are innate immune cytokines, such as IL-1, IL-25, and IL-33, as well as thymic stromal lymphopoietin. They are released from airway epithelial cells and can in turn activate T H 2 cells, type 2 innate lymphoid cells, or both. 3, 4 Another important cytokine is IL-9, expression of which is greater in the lungs of asthmatic patients. 5, 6 Moreover, transgenic expression of IL-9 has been shown to promote allergic inflammation.
7-9 IL-9 increases mucus production from lung epithelial cells and pulmonary mastocytosis. 10 More evidence of the importance of IL-9 in the development of allergic airway inflammation comes from an acute asthma model using ovalbumin (OVA)/alum immunization, followed by aerosolized airway OVA challenges, as a trigger for asthma development. Using this model, Cheng et al 11 found a significant decrease in airway hyperresponsiveness and bronchoalveolar lavage (BAL) eosinophilia after administration of an IL-9 blocking antibody. Additionally, a recent study showed that T H 9 cells were involved in lung allergic inflammation. 12 Adoptively transferred T H 9 cells lead to allergic airway disease characterized by increased amounts of eosinophil recruitment, tissue mast cell numbers, and serum anti-OVA IgE levels after OVA challenge, [13] [14] [15] supporting the contribution of T H 9 cells to allergic inflammation. However, it is also reported that IL-9 might not significantly affect allergic airway inflammation in mice. 16 Thus the inconsistency still needs to be clarified.
Depending on the surrounding cytokine milieu, naive CD4 1 T H cells are activated and differentiate into distinct subsets, including T H 1, T H 2, T H 9, and T H 17 cells or induced regulatory CD4
1

CD25
1 T cells (iTreg), which are characterized by differential cytokine-secreting profiles. 17, 18 IL-9-producing CD4
1 T H cells (T H 9 cells) are induced from naive CD4 1 T cells by TGF-b and IL-4 from naive CD4 1 T cells under the stimulation of the T-cell antigen receptor. T H 9 cells have been shown to participate in allergic inflammation, autoimmune diseases, and cancers. TGF-b alone without IL-4 promotes iTreg cells by inducing forkhead box protein 3 (Foxp3), 19, 20 whereas IL-4 alone supports T H 2 induction. IL-4 activates signal transducer and activator of transcription (STAT) 6 and interferon regulatory factor 4 (IRF4), whereas TGF-b activates PU.1 and represses T-box expressed in T cells (T-bet) and GATA3. It is the integration of those events that eventually drives IL-9 expression because either of these cytokine alone induces the differentiation into either regulatory T (Treg) or T H 2 cells. 21 Sequence and molecular analysis identified the potential binding sites for transcription factors, including PU.1, IRF4, STATs, nuclear factor of activated T cells, GATA1, GATA3, Smads, and Notch, as well as nuclear factor kB (NF-kB) and activator protein 1 (AP-1), in the promoter region of Il9. 12, 21, 22 However, the molecular regulatory network of T H 9 differentiation remains elusive thus far.
Wild-type p53-induced phosphatase 1 (Wip1; also called PP2Cd or PPM1D) is a serine/threonine protein phosphatase that belongs to the type 2Cd protein phosphatases. 23 Wip1, as a novel oncogene, [24] [25] [26] [27] is currently believed to be a promising therapeutic target for cancers. 28, 29 The involvement of Wip1 in the hematopoietic system recently received great attention. Wip1 critically regulates granulocyte development and function through p38 mitogen-activated protein kinase (p38MAPK)/ STAT1-dependent pathways. [30] [31] [32] [33] It is known that Wip1 is essential for the homeostasis of mature medullary thymic epithelial cells, maturation of T cells in the thymus, and antigen-independent B-cell development from hematopoietic stem cells in both p53-dependent and independent manners. [34] [35] [36] However, it remains unknown how Wip1 controls CD4
1 T-cell polarization into T H 1, T H 2, T H 9, T H 17, and iTreg cells. In the present study we used Wip1-deficient mice to address this issue. We found that Wip1 deficiency selectively impaired T H 9 cell differentiation through a c-Jun N-terminal kinase (JNK)-c-Jun/ c-Fos pathway. Interestingly, the reduction in T H 9 cell development leads to a decreased allergic response in an OVA-induced asthma mouse model, demonstrating the importance of this subset for allergy development. Moreover, administration of a specific Wip1 inhibitor significantly reduces the pathology of allergic airway inflammation in mice. Thus our study reveals a novel function of the phosphatase Wip1 in regulating T H 9 cell development and underlines the potency of Wip1 as a molecular target for the treatment of T H 9-mediated allergic inflammation. Our findings pave the way for the development of new and specific treatments of allergic asthma.
METHODS Mice
Wip1 knockout (KO) mice were provided by the Key Laboratory of Human Diseases Comparative Medicine, Ministry of Public Health, Beijing, China. Wip1 KO mice have been backcrossed to the C57BL/6 background in our laboratory. 30, 35 C57BL/6 (B6) mice were purchased from Beijing University Experimental Animal Center (Beijing, China). Recombination-activating gene 2 (Rag2) KO mice were purchased from Beijing Huafukang Animal Center (Beijing, China). All mice were bred and maintained under specific pathogen-free conditions in the animal facility of the Institute of Zoology, Chinese Academy of Science. Sex-matched littermate mice 8 to 12 weeks of age were used mainly for experiments. All animal studies were approved by the Animal Ethics Committee of the Institute of Zoology (Beijing, China).
Differentiation of CD4
1 T-cell subpopulations from naive T cells in vitro 
Flow cytometry
After 3 to 5 days of culture, cells were stimulated with phorbol 12-myristate 13-acetate (50 ng/mL) and ionomycin (500 ng/mL; Sigma-Aldrich, St Louis, Mo) for 5 hours at 378C, and GolgiStop (BD PharMingen, San Jose, Calif) was added to the cells for the last 3 hours of stimulation. Intracellular cytokine staining was carried out with Fixation/Permeabilization buffer solution, according to the manufacturer's protocol (BD Biosciences). Fluorochrome-conjugated anti-mouse IL-9 (RM9A4; BioLegend, San Diego, Calif), anti-mouse IL-4 (11B11; eBioscience), anti-mouse IL-13 (eBio13A; eBioscience), anti-mouse IL-17A (TC11; BioLegend), anti-mouse IFN-g (XMG1.2; BioLegend), anti-mouse TNF-a (MP6-XT22; BioLegend), anti-mouse PU.1 (7C2C34; BioLegend), anti-mouse IRF4 (IRF4.3E4; BioLegend), anti-mouse T-bet (4B10; BioLegend), and anti-mouse Foxp3 (NRRF-30; eBioscience) were used for staining. Foxp3, PU.1, IRF4, GATA3, and T-bet staining was carried out with Fixation/Permeabilization buffer solution, according to the manufacturer's protocol (eBioscience). Stained cells were analyzed on a FACSCalibur (BD Bioscience) or Epics XL (Beckman Coulter) with FCS Express 3 software.
Real-time PCR
Total RNA was extracted from cultured cells with a total RNA kit (Promega, Madison, Wis), and cDNA was synthesized with a cDNA Reverse Transcription kit (Takara Bio, Shiga, Japan). Quantitative real-time PCR was performed on the CFX96 Real-Time System (Bio-Rad Laboratories, Hercules, Calif) with Power SYBR PCR Master Mix (Applied Biosystems, Foster City, Calif). All real-time PCR reactions were carried out with an optical 96-well reaction plate and run in triplicates. 31 Each plate included 2 no-template controls. The primers used in the present study are summarized in Table I . Real-time PCR data were analyzed by using the comparative cycle threshold method and were normalized by using the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT).
ELISA
IL-9 in cell-culture supernatants and lung tissue homogenates was measured with the ELISA kit, according to the manufacturer's instructions (eBioscience). Lung tissue (200 mg) was homogenized in 1 mL of RIPA buffer and centrifuged (at 3000 rpm for 10 minutes), and the supernatant was collected. IL-17, TNF-a, IL-4, IL-5, IL-13, and mast cell protease 1 (MCP-1) were detected by using ELISA kits of IL-17 (BioLegend), TNF-a (BioLegend), IL-4 (BioLegend), IL-5 (BioLegend), IL-13, (eBioscience), and MCP-1 (eBioscience), according to the manufacturer's instructions. Levels of mouse OVA-specific IgG, IgG 2b , and IgG 1 in sera were detected by using the quantitative ELISA kit of mouse anti-OVA IgG (Chondrex, Redmond, Wash), mouse anti-OVA IgG 2b (Chondrex), and mouse anti-OVA IgG 1 (Chondrex), according to the manufacturer's instructions.
Induction of allergic airway inflammation
Allergic airway inflammation was induced, as previously described. 37 Mice 8 to 10 weeks of age were sensitized by means of intraperitoneal injection of OVA (Sigma-Aldrich) adsorbed with aluminum hydroxide (Sigma-Aldrich) at a dose of 10 mg of OVA per 1 mg of aluminum hydroxide (200 mL) on days 0 and 14. From day 21, mice were exposed to aerosolized OVA (1% wt/vol) for 30 min/d for 5 consecutive days. Mice were killed 2 days after the final intranasal challenge.
For studies with adoptive transfer of CD4 1 T cells, 1 3 10 7 sorted CD4
1
T cells of WT and Wip1 KO mice were adoptively transferred to Rag2 KO mice, respectively, by means of intravenous injection by 1 day before OVA sensitization. These mice then underwent OVA-induced allergic airway inflammation, as described above. Wip1 inhibitor (2.5 mg/mL, 25 mL per mouse) or the same dose of dimethyl sulfoxide was intraperitoneally injected into mice daily from day 20 to day 24 during the allergic airway inflammation induction phase to evaluate the effect of Wip1 inhibitor (CCT007093; Sigma-Aldrich) on mouse allergic airway inflammation.
The trachea was cannulated, and lungs underwent lavage with 3 mL of PBS. Cell numbers in BAL fluid were counted with a hemocytometer. Cells in BAL fluid were analyzed by using flow cytometry, with antibodies of CD11b (M1/70; eBioscience), Siglec-F (E50-2440; BD PharMingen), Ly6G (1-A8; BD Biosciences), CD3e (145-2C11; eBioscience), B220 (RA3-6B2; BioLegend), and F4/80 (BM8; eBioscience) analyzed. RNA was isolated from cells in BAL fluid for real-time PCR analysis. Peripheral immune responses in sensitized and challenged mice were assessed by means of culture of splenocytes for 72 hours with OVA (100 mg/mL). Lung tissue samples were prepared from control mice and mice in OVA-induced allergy inflammation, embedded in paraffin, and sectioned and then stained with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) for evaluation of the infiltration of inflammatory cells and mucin production in tracheas.
Airway hyperresponsiveness
For airway hyperresponsiveness detection, a FinePointe NAM System (Buxco Research Systems, Wilmington, NC) were used. In the FinePointe NAM System, specific airway resistance (sRaw) values represent airway hyperresponsiveness and lung function in mice. Allergic airway inflammation was induced in mice, as described above. Forty-eight hours after the last allergen challenge, WT and Wip1 KO mice were placed in the NAM plethysmograph and received nebulized PBS or increasing concentrations of methacholine (5, 10, 20, and 40 mg/mL) for 1 minute. After the mice respond to them for 1 minute, sRaw values were measured for 2 minutes. Results were shown as the fold increase relative to the sRaw value (baseline) before mice were treated with nebulized PBS or methacholine.
Immunoblotting
Naive CD4
1 T cells were cultured in RPMI 1640 medium with 10% FBS.
After stimulation, cells were washed once in cold PBS and lysed in RIPA buffer (50 mmol/L Tris-HCl [pH 7.4], 1% NP-40, 0.25% Na-deoxycholate, 150 mmol/L NaCl, and 1 mmol/L EDTA [pH 7.4]) with protease and phosphatase inhibitor cocktails (Roche, Mannheim, Germany) for 10 minutes on ice. Protein concentrations were determined by using a BCA assay. 38 The lysates were mixed with 53 SDS-PAGE loading buffer and boiled at 1008C for 5 minutes. Protein samples were size fractionated on 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Millipore, Temecula, Calif). After blocking for 1 hour, membranes were incubated with primary antibodies overnight at 48C. The appropriate horseradish peroxidase-conjoined secondary antibody was then added and detected by using chemiluminescence (Millipore). Actin was used as a protein loading control. Phospho-STAT6 (Tyr641), STAT6, phospho-Smad3 (Ser423/425), Smad3, phospho-p38MAPK (Thr180/Tyr182), P38, phospho-STAT5 (Tyr694), STAT5, phospho-STAT1 (Ser727), STAT1, phospho-SAPK/JNK (Thr183/Tyr185), SAPK/JNK, phospho-c-Jun (Ser73), c-Jun, Rel-B, NF-kB p65, b-actin, and histone H3 were purchased from Cell Signaling Technology (CST, Danvers, Mass).
Luciferase assay
Luciferase reporter assays were performed, as reported previously. 39 The mouse Il9 promoter region (22162 to 128) was amplified from genomic DNA by using PCR with a forward primer (59-TCGacgcgtGATGACCTGT GACCTGAC-39) and a reverse primer (59-TCCcccgggCAGAGGCAAG GATGTATGT-39). Lowercase letters in primers were MluI and SmaI sites introduced to allow forced cloning into the pGL3 basic luciferase reporter gene vector. HEK 293T cells were transfected with the reporter vector together with expression plasmids containing cDNA encoding mouse c-Jun and c-Fos and the pRL-TK vector (Promega) as an internal control through the use of Lipofectamine 2000 method (Invitrogen, Carlsbad, Calif). After 24 hours, Il9 promoter activity was assessed by using a dual-luciferase reporter assay system, according to the manufacturer's instructions (Promega). All samples were normalized for transfection efficiency by means of division of firefly luciferase activity by Renilla luciferase activity, and the assays were repeated 3 times.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were carried out, as previously described. 40 WT and Wip1 KO CD4
were purified by means of magnetic cell sorting (STEMCELL Technologies) and cultured at a density of 1 3 10 6 cells per well. After stimulation in T H 9-inducing conditions for 3 days, cells were collected and then fixed for 10 minutes at room temperature with 1% formaldehyde (Sigma-Aldrich) and lysed in lysis buffer. Lysates were sonicated, followed by precipitation with anti-cJun (Abcam, Cambridge, United Kingdom), control rabbit IgG (Abcam), anti-PU.1 (CST), and anti-IRF4 (CST). Immunoprecipitated DNA was reverse cross-linked, extracted with phenol and chloroform, and then analyzed by using real-time PCR with Il9-c-Jun forward primer (59-AGAACCCGAC-TATTTGAAGAGCATC-39) and reverse primer (59-CTCAGTCTACCAGCA TCTTCCA-39), Il9-PU.1 forward primer (59-GTCACTTGACAAAGG CTGTCTTATGCC-39) and reverse primer (59-GTCACTTGACAAAGGC TGTCTTATGCC-39), and Il9-IRF4 forward primer (59-GATTCTCACAAC CAGAATTCCTGC-39) and reverse primer (59-CTACCAGCATCTTCCA GTCTAGC-39).
Statistical analysis
All data were presented as means 6 SDs. The unpaired 2-tailed Student t test was used for data of 2 groups. Data from more than 2 groups were subjected to 1-way ANOVA with SAS 9.2 software (SAS, Institute, Cary, NC). Comparisons were considered statistically significant when the P value was less than .05.
RESULTS
Wip1 deficiency does not affect T H 1, T H 2, and T H 17 cell differentiation
To investigate the involvement of Wip1 in T H cell subtype development, we used Wip1 KO mice and first analyzed whether Wip1 is required for naive T-cell activation and proliferation. The sorted naive CD4 1 T cells from WT and Wip1-deficient mice were activated with anti-CD3/anti-CD28 mAbs in vitro. As shown in Fig 1, naive Wip1-deficient CD4 1 T cells proliferated as efficiently as WT cells after activation, as determined by using carboxyfluorescein succinimidyl ester dilution assays (Fig 1, A) . Consistently, naive WT and Wip1 KO CD4
1 T cells showed comparable upregulation of activation markers, such as CD25 and CD69 molecules, after stimulation with anti-CD3/ anti-CD28 mAbs (Fig 1, B and C) . Thus these data indicate that Wip1 is not required for naive CD4
1 T-cell activation in terms of cell proliferation and activation marker expression.
Next, we explored the potential roles of Wip1 in CD4 1 T-cell polarization and differentiation by using the standard in vitro cytokine cocktail induction systems for distinct T H subsets. Naive Wip1-deficient CD4
1 T cells differentiated into T H 1, T H 2, and 
T H 17 cells as efficiently as naive WT CD4
1 T cells in the corresponding culture systems, respectively, as detected by using real-time PCR and intracellular cytokine staining with flow cytometry (Fig 1, D-I) . 1 T cells (see Fig E2) . However, we found slightly but significantly higher Foxp3 mRNA expression in naive Wip1-deficient CD4 1 T cells when induced for CD4 1
Foxp3
1 iTreg cell differentiation compared with that in naive WT CD4
1 T cells (Fig 1, J) . These observations were further supported by the increased percentage of Foxp3 1 T cells in Wip1-deficient CD4
1 T cells than in WT CD4 1 T cells under iTreg cell induction conditions (Fig 1, K) . Therefore Wip1 deficiency does not intrinsically influence T H 1, T H 2, and T H 17 cell differentiation in vitro, despite a slight increase in Foxp3 expression under iTreg cell induction.
Wip1 controls T H 9 cell development
Recently, T H 9 cells have been defined by secreting large amounts of IL-9 but less IL-4, IL-5, and IL-13 on activation (Fig 1, B) and CD69 (Fig 1, C 1 T cells expressed high Il9 levels, as detected by using real-time PCR (Fig 2, A) , when activated with anti-CD3/anti-CD28 mAbs in the presence of TGF-b and different doses of IL-4 to induce T H 9 cells, as reported previously. 42 However, Wip1-deficient CD4 1 T cells expressed remarkably less Il9 mRNA than WT CD4 1 T cells under the same polarization settings (Fig 2, A) . Decreased Il9 expression at the mRNA level in the induced Wip1-deficient CD4
1 T cells was further confirmed by reduced concentrations of IL-9 in the culture medium, as indicated by means of ELISA (Fig 2, B) . Consistently, we also observed the decreased frequency of IL-9
1 T cells in Wip1-deficient CD4 1 T cells, as determined with flow cytometry (Fig 2, C) . Furthermore, during T H 9 differentiation in vitro, lower expression levels of Il9 in Wip1-deficient CD4 1 T cells were observed at all culture time points (Fig 2, D) , excluding the possibility that the decreased Il9 expression is simply due to altered response kinetics. As expected, WT T H 9 cells expressed extremely low levels of T H 2 cytokines, such as Il4, Il5, and Il13, compared with T H 2 cells, and Wip1-defeicient T H 9 cells expressed lower T H 2 cytokine levels (see Fig E3 in 1 T cells were cultured in the T H 9-inducing system (Fig 2, E) . The low level expression of IL-4, IL-5, IL-13, and Foxp3 in T H 9-inducing Wip1 KO CD4 1 T cells indicated that the poor T H 9 differentiation in the absence of Wip1 is not due to the skewed differentiation into either IL-4-induced T H 2 cells or TGF-b-induced Foxp3 1 T cells. It is known that CCT007093 is a Wip1-specific inhibitor. [43] [44] [45] Thus we examined the effects of CCT007093 on T H 9 cell differentiation in vitro. Consistent with impaired T H 9 differentiation of Wip1-deficient CD4 1 T cells, the Wip1-specific inhibitor CCT007093 significantly inhibited Il9 mRNA expression in WT CD4
1 T cells in a dose-dependent manner (Fig 2, F) . However, CCT007093 did not further inhibit Il9 mRNA expression in Wip1 KO CD4 1 T cells (Fig 2, F) , indicating that the inhibitory effect of CCT007093 on Il9 expression in CD4 1 T cells is mainly mediated through a Wip1-dependent pathway. Furthermore, we showed that CCT007093 treatment significantly decreases the percentage of CD4 1
IL-9
1 T cells when assessed by using intracellular fluorescence-activated cell sorting staining (Fig 2, G) . We also confirmed that Wip1 inhibitor did not significantly influence T H 1 and T H 2 differentiation (see Figs E4 and E5 in this article's Online Repository at www.jacionline. org) and slightly promoted CD4 Altogether, we conclude that Wip1 is selectively required for T H 9 cell development in a cell-autonomous manner.
Wip1 regulates T H 9 cell development through the JNK-c-Jun/c-Fos pathway
To understand the molecular mechanisms underlying impaired T H 9 differentiation caused by Wip1 deficiency, we first examined expression of the transcription factors PU.1 and IRF4, which play important roles in T H 9 development. 12, 13 Indeed, induced WT and Wip1-deficient T H 9 cells expressed similar levels of PU.1 and IRF4, as determined by using flow cytometry (see Fig E7 in this article's Online Repository at www.jacionline.org). Furthermore, ChIP assays demonstrated that both PU.1 and IRF4 display similar binding ability to the Il9 gene promoter between WT and Wip1-deficient T H 9 cells (see Fig E7) .
We then screened the candidate molecules downstream of Wip1 and the potential targets known to regulate T H 9 cell development by analyzing WT and Wip1 KO T H 9 cells with Western blotting and real-time PCR. Under T H 9 induction, we noticed increased activation of Stat6, Stat5, Stat1, Smad3, p38MAPK, JNK, c-Jun, RelB, and p65 molecules in WT naive CD4 1 T cells, as indicated by their protein phosphorylation and their localization into the nuclei (Fig 3, A and B) . However, compared with their WT counterparts, Wip1 KO CD4 1 T cells displayed enhanced activation of p38MAPK, Stat1, JNK, and c-Jun, but activation of the Stat6, Stat5, Smad3, and NF-kB pathways remained comparable during T H 9 induction (Fig 3, A  and B) , indicating the potential involvement of the p38MAPK, Stat1, JNK, and c-Jun pathways in the decreased T H 9 differentiation caused by Wip1 deficiency.
Moreover, inhibition of p38MAPK and Stat1 by SB203580 and methylthioadenosine, respectively, 39 did not rescue the poor differentiation of Wip1 KO T H 9 cells (see Fig E8 in this article' s Online Repository at www.jacionline.org), suggesting that the increased p38MAPK and Stat1 activity in Wip1 KO T cells might not be responsible for reduced T H 9 cell differentiation. SP600125, a widely used JNK inhibitor, 46 decreased JNK activation and c-Jun activation in WT and Wip1 KO T cells during T H 9 induction (Fig 3, C) . Intriguingly, SP600125 greatly rescued the deficient T H 9 differentiation in Wip1-deficient T H cells, as measured by using real-time PCR and intracellular staining with flow cytometry (Fig 3, D and E) . These results reveal that Wip1 regulates T H 9 cell differentiation through its inhibition of JNK-dependent pathways.
The Il9 promoter region and 2 additional regions of conserved noncoding sequence upstream of the promoter region form the cis-and trans-regulatory elements, collectively regulating Il9 gene expression. 12, 21 Sequence and bioinformatics analysis have identified the potential binding sites for transcription factors, including PU.1, IRF4, STATs, nuclear factor of activated T cells, GATA1, Smads, and Notch, as well as NF-kB and AP-1, in the promoter region of Il9.
21,22 Therefore we investigated whether AP-1 can directly bind to the Il9 gene promoter and regulate Il9 expression. With ChIP assays, we noticed enhanced c-Jun binding to the Il9 promoter during WT and Wip1 KO T H 9 induction (Fig 3, F) . There are 2 potential binding sites for AP-1 located at 2385 and 2166 of the Il9 promoter (Fig 3, G) . In a luciferase reporter system with HEK 293T cells, overexpression of c-Jun and c-Fos significantly decreased Il9 promoterdriving luciferase activity in a dose-dependent manner (see Fig  E9 in this article's Online Repository at www.jacionline.org). Importantly, mutation of the AP-1 binding site located at 2385 of the Il9 promoter (Mut2) completely reversed the inhibitory effect of c-Jun/c-Fos on Il9 expression, as indicated by luciferase activity, but mutation of the AP-1 binding site at 2166 of the Il9 promoter (Mut1) did not do so (Fig 3, H) . Thus the AP-1 binding site at 2385 of the Il9 promoter is essential for the inhibitory role of AP-1 on Il9 expression. On the other hand, Wip1 KO CD4 1 T cells expressed similar levels of GATA3, basic leucine zipper ATF-like transcription factor (BATF), and Bcl6, which are also important for T H 9 differentiation [47] [48] [49] compared with WT CD4
1 T cells (see Fig E7) . Altogether, we conclude that Wip1 deficiency inhibits Il9 transcription through enhanced c-Jun/c-Fos binding to the promoter region.
Wip1 KO mice show a reduced allergic airway response
We next used an OVA-induced allergic airway inflammatory mouse model in which T H 9 cells play a critical role, as reported recently. 18, 19, 42, 50 The airway hyperresponsiveness of WT and Wip1 KO mice with OVA-induced allergic airway inflammation was detected by using a FinePointe NAM System. 51 Compared with WT mice, Wip1 KO mice demonstrated significantly less airway hyperresponsiveness in response to methacholine challenge (Fig 4, A) . We found significantly higher levels of OVA-specific IgE, OVA-specific IgG 1 , and OVA-specific IgG in the sera of WT littermates after an OVA-induced allergic response, as determined by using ELISAs (Fig 4, B , and see Fig  E10 in this article's Online Repository at www.jacionline.org), which is consistent with previous reports. 50 However, Wip1 KO mice have lower OVA-specific IgE, OVA-specific IgG 1 , and OVA-specific IgG production after similar OVA induction (Fig  4, B, and see Fig E10) . There were no detectable differences regarding OVA-specific IgG 2b levels between WT and Wip1 KO mice (see Fig E10) , which is mainly regulated by T H 1 cells. Mucus production in the bronchus of lung tissues reflects the severity of allergic inflammation and can be evaluated by using PAS reagent staining. 52 Wip1 KO mice produced less mucus in lung tissues compared with that seen in WT mice in an OVA-induced allergic airway inflammatory model, which was indicated by arrows (Fig 4, C) . Consistently, the mRNA expression of Muc5ac, which is associated with mucus hypersecretion, 41, 53 in lung tissues of OVA-induced Wip1 KO mice was significantly lower than that of WT mice (Fig 4, D) . Mast cells also play important roles in allergic airway inflammation and mouse MCP-1 levels in sera reflect the infiltration of mast cells in tracheal. 41 We found that MCP-1 levels in sera and Mcpt1 mRNA expression in lung tissues were significantly lower in OVA-induced allergic airway inflammatory Wip1 KO mice compared with those in their WT counterparts (Fig 4, E , and see Fig E11 in this article' s Online Repository at www.jacionline.org). H&E staining showed that Wip1 KO mice had less severe pathogenesis of allergic inflammation in the lung tissues than WT mice, as indicated by reduced pathologic changes (Fig 4, F) . The resistance to OVA-induced allergic airway inflammatory response of Wip1 KO mice was further supported by the significantly decreased infiltration by leukocytes and eosinophils in BAL fluid after OVA challenge (Fig 4, G and  H) . Moreover, freshly isolated cells from the BAL fluid and spleens of allergic airway inflammatory Wip1 KO mice expressed significantly less Il9, as detected by using quantitative PCR (Fig 4,  I and J) . Freshly isolated CD4
1 T cells from spleens of OVA-challenged Wip1 KO mice expressed fewer IL-9 molecules than CD4 1 T cells from those of OVA-challenged WT mice after stimulation with OVA in vitro (Fig 4, K) . However, cells isolated from the BAL fluid of Wip1 KO mice with allergic airway inflammation expressed similar levels of IL-4, IL-5, IL-13, IFN-g, and IL-17 as those of WT mice with allergic airway inflammation, as detected by using quantitative PCR (see Fig  E12 in this article' s Online Repository at www.jacionline.org). Il9 promoter luciferase vector. Cells were lysed, and luminescence was measured 24 hours later. Data are shown as means 6 SDs (n 5 3), representing 1 of at least 2 independent experiments. *P < .05 and **P < .01.
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Thus deficiency of Wip1 impairs T H 9 polarization in vivo and reduces T H 9 cell-mediated allergic airway inflammation.
Wip1 deficiency in CD4 1 T cells affects allergic airway inflammation in mice
To determine whether Wip1 deficiency in CD4
1 T cells alone is sufficient for the alleviative allergic immune response in an OVA-induced asthma mouse model, we assessed the severity of allergic airway inflammation in Rag2 KO mice that were adoptively transferred with the sorted Wip1 KO or WT CD4 1 T cells before mice were sensitized for allergic airway inflammation induction. We observed similar levels of CD4 1 T cells in the peripheral blood of Rag2 KO mice with transfer of the sorted WT or Wip1 KO CD4
1 T cells (Fig 5, A) , indicating that Wip1 deficiency does not affect the reconstitution ability of CD4 1 T cells after adoptive transfer to immune-deficient recipients. Rag2 KO mice receiving Wip1 KO CD4 1 T cells had less severe pathogenesis of allergic airway inflammation in lung tissues than mice with WT CD4
1 T-cell transfer, as indicated by reduced pathologic changes (Fig 5, B) . The reduced OVA-induced allergic inflammatory response with Wip1 KO CD4 1 T-cell transfer was further supported by less infiltration by leukocytes and eosinophils in the BAL fluid after OVA challenge (Fig 5, C and D) . Furthermore, Rag2 KO mice receiving Wip1 KO CD4 1 T cells produced less mucus in lung tissues compared with their counterparts harboring WT CD4 1 T cells, as evaluated by using PAS staining and Muc5ac mRNA expression in lung tissues (Fig 5, E and F) . Meanwhile, serum MCP-1 levels and mRNA expression of Mcpt1 in lung tissues A, Airway hyperresponsiveness of allergic airway inflammatory mice was examined by using a FinePointe NAM System, as described in the Methods section. sRaw represents airway hyperresponsiveness and lung function in mice. The uninduced mice serves as control animals. MCH, Methacholine. B, Levels of OVA-specific IgE in the sera of WT and Wip1 KO mice with or without OVA-induced allergic airway inflammation (AAI; n 5 4-6 per group). C, PAS reagent staining was performed on lung tissues of WT and Wip1 KO mice 48 hours after the last OVA challenge. Original magnification 3100. D, Muc5ac mRNA expression in lung tissues of WT and Wip1 KO mice. E, Mouse MCP-1 levels in sera of WT and Wip1 KO mice. F, H&E staining of lung tissues of WT and Wip1 KO mice and cell numbers of WT and Wip1 KO mice in BAL fluid. Original magnification 3100. G, Percentages of eosinophils in BAL fluid of WT and Wip1 KO were assessed by using flow cytometry. H, Quantification of cells in BAL fluid and lung infiltrates from WT and Wip1 KO mice (n 5 4-6 per group) in an allergic asthma model. I, Il9 mRNA expression in cells of BAL fluid isolated from WT and Wip1 KO mice. J and K, Il9 mRNA expression (Fig 4, J) and intracellular IL-9 staining (Fig 4, K) in splenocytes of WT and Wip1 KO mice (n 5 4-6 per group) stimulated for 3 days with OVA. Data represent 2 or 3 independent experiments. Data are shown as means 6 SDs. **P < .01.
of allergic inflammatory Rag2 KO mice receiving Wip1 KO CD4 1 T cells were significantly lower than those Rag2 KO mice transferred with WT CD4 1 T cells (Fig 5, G, see Fig E13 in this article's Online Repository at www.jacionline.org). Moreover, levels of IL-9 in lung tissues of Rag2 KO mice receiving Wip1 KO CD4 1 T cells were significantly lower, as detected by means of ELISA (Fig 5, H) . Freshly isolated CD4 1 T cells from the draining lymph nodes (dLNs) of OVA-challenged Rag2 KO mice receiving Wip1 KO CD4 1 T cells expressed less IL-9 than CD4 1 T cells from Rag2 KO mice harboring WT CD4 1 T cells (Fig 5, I ). Furthermore, we observed reduced amounts of secreted IL-9 in culture supernatants of dLN cells from Rag2 KO mice receiving Wip1 KO CD4 1 T cells (Fig 5,  J) . However, the cells isolated from BAL fluid of Wip1 KO CD4 1 T cell-reconstituted Rag2 KO mice expressed similar levels of IL-4, IL-5, and IL-13 compared with those of mice received WT CD4 1 T cells, as detected by using quantitative PCR (see Fig E14 in I, IL-9 expression of CD4 1 T cells of dLNs of allergic inflammatory Rag2 KO mice that received WT and Wip1 KO CD4 1 T cells (n 5 5 per group). J, Protein levels of IL-9 in the culture medium of cells isolated from dLNs after stimulation with OVA for 3 days. Data (mean 6 SD) represent 1 of 2 independent experiments. *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 is mainly mediated by IL-9 in our model, although IL-4, IL-5, and IL-13 are also involved in the pathogenesis of allergic airway inflammation, as reported previously.
54-57
Wip1 inhibitor decreased the severity of allergic airway inflammation in mice
Given the fact that Wip1 KO mice and Rag2 KO mice receiving Wip1 KO CD4
1 T cells exhibit resistance to the allergic immune response, we thus explored whether inhibition of Wip1 by CCT007093 44, 45 could block allergic pathogenesis in an OVA-induced allergic airway inflammatory mouse model. CCT007093 is a Wip1-specific inhibitor to suppress tumor cell growth and promote liver regeneration in vivo. 44, 58, 59 It inhibits Wip1 activity specifically and subsequently increased the phosphorylation of the known Wip1 target molecules. 43, 60 Administration of Wip1 inhibitor for 5 days during the induction stage could significantly reduce the severity of allergic inflammation in WT mice, as evidenced by reduced pathologic changes (Fig 6, A) . The reduced allergic inflammation was further confirmed by much less infiltration of leukocytes and eosinophils into the BAL fluid (Fig 6, B and C) and significantly decreased OVA-specific IgE levels in the sera (Fig 6, D) in the Wip1 inhibitor-treated mice. In addition, PAS staining and Muc5ac mRNA expression of lung tissues showed that mice treated with the Wip1 inhibitor CCT007093 produced less mucus in bronchus of lung tissues (Fig 6, E and F) . Serum MCP-1 levels and Mcpt1 mRNA expression in lung tissues were significantly decreased in mice treated with Wip1 inhibitor (Fig 6, G , and see Fig E15 in this article's Online Repository at www.jacionline.org). The mRNA expression of Il9 was significantly decreased in the cells of BAL fluid after Wip1 inhibitor CCT007093 treatment (Fig 6,  H) . Meanwhile, the homogenate of lung tissues of Wip1 inhibitor-treated allergic inflammatory mice expressed significantly less IL-9, as detected by means of ELISA (Fig 6, I) . We also observed reduced frequency of freshly isolated CD4
1
T cells expressing IL-9 from dLNs of CCT007093-treated allergic inflammatory mice (Fig 6, J) . In addition, CCT007093 treatment did not affect IL-4, IL-5, IL-13, IFN-g, IL-17, and TNF-a expression (see Fig E16 in 
DISCUSSION
Asthma is one of the most common chronic diseases affecting millions of persons worldwide. Current clinical therapies based on inhaled corticosteroids and long-acting b 2 -agonists are effective in controlling asthma in most but not all patients. 1 Here we found that treatment with the phosphatase Wip1 inhibitor CCT007093, 45 which has been proved to inhibit proliferation of several types of cancer cells, significantly decreased the pathogenesis of allergic airway inflammation in a mouse model. Wip1 inhibition significantly reduced pathologic changes in the lungs, eosinophil infiltration in BAL fluid, mucus in bronchus of lung tissues, and OVA-specific IgE levels in sera of asthmainduced mice. The role of Wip1 in allergic airway inflammation was further confirmed with Wip1-deficient mice. Thus Wip1 inhibitors might have potential application to treat allergic inflammatory diseases.
Asthma is a chronic inflammatory disease of the airways characterized by infiltration of eosinophils, basophils, mast cells, and CD4 T H cells into the airway submucosa, which are important cells underlying allergic eosinophilic asthma. 2, 3 The role of IL-9 in allergic asthma is currently recognized. IL-9 expression is greater in the lungs of asthmatic patients, and transgenic expression of IL-9 results in allergic inflammation. 5, 6, 8, 9 IL-9 promotes mucus production from lung epithelial cells and pulmonary mastocytosis. 10, 11 However, it is also reported that IL-9 might not be involved in allergic airway inflammation in mice. 16 The inconsistency is unclear right now. Our present studies show that Wip1 selectively affects T H 9 cell differentiation and deficiencies of Wip1 through genetic modification or that a chemical inhibitor reduces the pathogenesis of allergic airway inflammation in mice, indicating that the T H 9 cell subpopulation might contribute to the pathologic changes of allergic asthma. This speculation is in line with a recent study showing that T H 9 cells were involved in lung allergic inflammation. 12 Adoptive transferred T H 9 cells lead to allergic airway disease characterized by increased amounts of eosinophil recruitment, tissue mast cell numbers, and serum IgE levels after OVA challenge. [13] [14] [15] 42 All these data support the contribution of T H 9 cells to allergic airway inflammation.
With the different T H cell subpopulation-inducing systems, we found that Wip1 did not significantly affect the differentiation of T H 1, T H 2, and T H 17 cells. Wip1 deficiency slightly but significantly increased the differentiation of CD4
1
CD25
1 iTreg cells. However, either genetic deficiency or inhibition of Wip1 activity through its specific inhibitor selectively impaired T H 9 cell differentiation. The poor T H 9 differentiation of Wip1 KO naive CD4
1 T cells is unlikely caused by T-cell activation failure because sorted naive CD4
1 T cells proliferated efficiently and expressed comparable levels of activation markers, such as CD25 and CD69, on anti-CD3/CD28 mAb stimulation compared with WT naive CD4 1 T cells. Altogether, our observations support that phosphatase Wip1 intrinsically regulates T H 9 cell differentiation.
Wip1 KO naive CD4 1 T cells displayed higher activation of p38MAPK, Stat1, JNK, and c-Jun than WT cells during T H 9 induction, as indicated by their protein phosphorylation and localization into the nuclei, whereas WT and Wip1 KO CD4 1 T cells showed similar activation of Stat6, Stat5, and Smad3 proteins and the NF-kB pathway. However, specific inhibition of p38MAPK and Stat1 by SB203580 and methylthioadenosine, respectively, 39 did not rescue the poor differentiation of Wip1 KO T H 9 cells, indicating that the increased p38MAPK and Stat1 activity in Wip1 KO T cells is not responsible for impaired T H 9 cell differentiation. PU.1 and IRF4 represent 2 important transcription factors for T H 9 cell differentiation.
12,13 However, we did not observe any significant difference regarding either PU.1 and IRF4 expression or their binding to Il9 promoter between WT and Wip1 KO T H 9 cells. Therefore PU.1 and IRF4 might not contribute to the defective differentiation of T H 9 cells caused by Wip1 deficiency. Interestingly, the JNK inhibitor SP600125 significantly decreased c-Jun activation and rescued the deficiency of Wip1 KO T H 9 differentiation. These results suggest that Wip1 can regulate T H 9 cell differentiation through a JNK-dependent pathway. Our ChIP assays further reveal enhanced c-Jun binding to Il9 promoter in Wip1 KO T H 9 cells, which are in line with previous reports showing the potential binding sites of Il9 promoter region for the transcription factor AP-1. 21, 22 Furthermore, overexpression of c-Jun and c-Fos significantly decreased Il9 promoter-driving luciferase activity in a dose-dependent manner. We further demonstrate that the AP-1 binding site at 2385 of the Il9 promoter is essential for inhibiting Il9 expression. On the other hand, Wip1 KO CD4 1 T cells expressed comparable levels of GATA3, BATF, and Bcl6, which are also important for T H 9 induction, [47] [48] [49] as WT CD4 1 T cells during T H 9 induction. Collectively, we conclude that phosphatase Wip1 deficiency reduces Il9 gene transcription through enhanced binding of c-Jun/c-Fos to the promoter, which is activated by JNK. These findings shed light on a previously unrecognized role of Wip1 in T H 9 cell differentiation.
Wip1, as a novel oncogene, [24] [25] [26] [27] is believed to be a promising therapeutic target for cancers. 28, 29 It was recently reported that the Wip1 inhibitor CCT007093 could promote liver regeneration in mice. 44 In the present study we show that CCT007093 significantly decreases allergic airway inflammation and that Wip1-deficient mice are resistant to allergic airway inflammation, J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 indicating that Wip1 might be essential for the sensitization and induction of allergic airway inflammation in OVA-induced asthma mice. However, the Wip1 inhibitor CCT007093 was given during allergic airway inflammation induction but not during mouse sensitization by means of OVA immunization, and thus Wip1 inhibitors have potential in the treatment allergic airway inflammation.
T H 2 cells are well recognized to be involved in the setting of allergic airway inflammation. 61, 62 Recently, accumulating evidence suggests that T H 9 cells and IL-9 can also play a critical role in allergic airway inflammation, although this remains debated. 7, 13, 16, 18, 63 Those discrepancies might be related to different animal models, treatment approaches, or distinct time points. This can also reflect the complexity regarding T H 9 cells in allergic inflammation. With an adoptive transfer mouse model in which Rag2 KO mice received either WT or Wip1KO CD4 1 T cells, we present the data that Wip1-deficient T H 9 cells ameliorate the pathogenesis of allergic airway inflammation. The key players for decreased allergic airway inflammation mediated by Wip1-deficient T H 9 cells in mice remain to be investigated. It is likely that IL-9 produced by T H 9 cells is the main mediator in our model; the involvement of other cytokines, such as IL-13, in this process needs to be determined further.
In summary, we have uncovered a novel role of Wip1 in regulating T H 9 cell development through JNK-dependent c-Jun/c-Fos-mediated direct inhibition on Il9 transcription. Our findings that the Wip1 inhibitor significantly decreased progression of mouse allergic airway inflammation might have important implications for clinical application of Wip1 inhibitors in allergy therapies.
